Other Services

KLH

KLH Conjugates as Vaccines
KLH (keyhole limpet hemocyanin) is a potent immune-modifying carrier protein that increases the efficacy of antigens including peptides, carbohydrates, glycolipids, and other immunogenic molecules with potential as API¡¯s in therapeutic vaccines. The KLH conjugate platform is currently under study in early to late-stage clinical trials as potential treatment for cancer, arthritis, hypertension, and many other disorders. KLH is extracted from aqua-cultured Megathura crenulata and purified into native intermediates and constituent subunits under full cGMP compliance. Dependable, plentiful, safe supplies of KLH are available for every stage of conjugate vaccine development from discovery to commercialization.

KLH: preferred carrier for conjugate vaccines

    Potent immunogenicity of KLH Proven safety of KLH
  • High molecular weights
    		•
  • Non-mammalian source: no risk of TSE
    		•
  • Potent T-cell epitopes
    		•
  • Dozens of advanced clinical trials in progress
    		•
  • Wealth of available conjugation chemistries
    		•
  • Thousands of patients immunized without adverse effects
    		•
  • Multiple sites for highdensity antigen conjugation
    		•
  • Fully documented pathogen and endotoxin testing
    		•
  • Novel neoantigen ensures robust immunological response
    		•
  • Aqua-culture source provides the highest degree of regulatory
    		•
  • compliance and raw material control
    		•

Subunit KLH is now available for cGMP production of conjugate vaccines. The subunit form of KLH offers lower molecular weight and improved solubility relative to native KLH forms.